CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Oberland pours up to $400M into MeiraGTx eye gene therapies

Positive
AI Analysis

Summary

Oberland has committed up to $400M in funding to MeiraGTx to support development of multiple late-stage eye gene therapy candidates, including a program recently reacquired from Johnson & Johnson.

Importance:6/10
Sentiment:
0.70
gene therapyophthalmologyfundinglate-stage development
Related Companies

Read the original article

Published by BioPharma Dive on July 7, 2026 4:17 PM

Read Original